Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Amortizatization of Intangibles (2017 - 2023)

Rein Therapeutics filings provide 7 years of Amortizatization of Intangibles readings, the most recent being -$188000.0 for Q4 2023.

  • For the quarter ending Q4 2023, Amortizatization of Intangibles fell 252.85% year-over-year to -$188000.0, compared with a TTM value of -$188000.0 through Sep 2024, down 167.38%, and an annual FY2023 reading of -$32000.0, down 115.38% over the prior year.
  • Amortizatization of Intangibles hit -$188000.0 in Q4 2023 for Rein Therapeutics, down from $1000.0 in the prior quarter.
  • The five-year high for Amortizatization of Intangibles was $123000.0 in Q4 2022, with the low at -$188000.0 in Q4 2023.
  • Median Amortizatization of Intangibles over the past 5 years was $12000.0 (2020), compared with a mean of $8800.0.
  • The sharpest move saw Amortizatization of Intangibles crashed 1400.0% in 2021, then skyrocketed 3333.33% in 2023.
  • Year by year, Amortizatization of Intangibles stood at $61000.0 in 2019, then crashed by 116.39% to -$10000.0 in 2020, then crashed by 180.0% to -$28000.0 in 2021, then soared by 539.29% to $123000.0 in 2022, then tumbled by 252.85% to -$188000.0 in 2023.
  • According to Business Quant data, Amortizatization of Intangibles over the past three periods came in at -$188000.0, $1000.0, and $52000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.